Healthcare Services company Vimta Labs announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Total Income for Q2FY25 was at Rs 854 million. EBITDA for Q2FY25 was Rs 306 million; EBITDA margin was at 35.8%. PBT for Q2FY25 was at Rs 219 million. Q2FY25 PAT was at Rs 170 million; PAT margin was at 19.9%. Basic EPS in Q2FY25 was Rs 7.7. H1FY25 Financial Highlights: Total Income for H1FY25 was at Rs 1,610 million. EBITDA for H1FY25 was Rs 572 million; EBITDA margin was at 35.5%. PBT for H1FY25 was at Rs 401 million. H1FY25 PAT was at Rs 309 million; PAT margin was at 19.2%. Basic EPS in H1FY25 was Rs 13.9. Total Debt as of 30th September 2024 stood at Rs 116 million. Cash and Cash equivalents including bank balance stood at Rs 278 million as of 30th September 2024. Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to report a strong operational performance for Q2FY25, with revenues of Rs 854 million, reflecting a 26.4% YoY growth. Our EBITDA rose by 57.3% YoY, and net profit surged by 109.9%. This performance was primarily driven by our pharmaceutical services, which continue to lead the business. As stated in our August 30, 2024, press release, Vimta Labs has divested the Diagnostic and Pathological services business to Thyrocare Technologies. This decision allows us to sharpen our focus on core services and optimize resources for sustained growth, resulting in a significant improvement in our EBITDA margins, which now exceed 35%, up from the previous range of 23% to 30%. Looking ahead, our Pharmaceutical services continue to show promising growth, and we anticipate that our food testing services will also contribute to growth in coming quarteRs We are also expanding our electrical and electronics testing capabilities and preparing to commission a new facility in couple of quarteRs We remain committed to driving sustainable and impactful growth for our investors.” Result PDF
Conference Call with Vimta Labs Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Vimta Labs announced Q1FY25 results: Total Income for Q1FY25 was at Rs 824 million EBITDA for Q1FY25 was Rs 252 million; EBITDA margin was at 30.6% PBT for Q1FY25 was at Rs 165 million Q1FY25 PAT was at Rs 123 million; PAT margin was at 14.9% Basic EPS in Q1FY25 was Rs 5.5 Total Debt as of June 30, 2024 stood at Rs 130 million Cash and Cash equivalents were at Rs 324 million as of June 30, 2024 Q1FY25 Capex spent was at Rs 164 million Debt to Equity ratio was 0.04x Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to report stable business momentum with encouraging QoQ sales growth and stable EBITDA margins. Despite a challenging internal and external environment, we achieved a QoQ growth in sales, driven by Pharmaceutical services which demonstrated sustained growth, albeit slightly tempered by the other services. Looking ahead, we are pleased to share that our new Life Sciences facility expansion will become operational in Q2 of this financial year. This facility is expected to play a significant role in driving our growth in the coming quarters. We remain optimistic about the future and are dedicated to fostering sustainable growth." Result PDF
Conference Call with Vimta Labs Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Vimta Labs announced consolidated Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Total Income for Q4FY24 was at Rs 802 million EBITDA for Q4FY24 was Rs 249 million; EBITDA margin was at 31.1% Q4FY24 PAT was at Rs 124 million Basic EPS in Q4FY24 was Rs 5.6 FY24 Financial Highlights: Total Income for FY24 was at Rs 3,223 million EBITDA for FY24 was Rs 908 million; EBITDA margins at 28.2% FY24 PAT was at Rs 410 million Basic EPS was Rs 18.5 in FY24 Cash flow From Operations at Rs 609 million for FY24; FY24 Capex at Rs 763 million Cash and Cash equivalents at Rs 258 million as of 31st March 2024 Debt to Equity ratio 0.06x Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs Limited, said: “Q4 maintained good recovery after H1 being harsh on us. Having a strong and resilient business model has helped us strive through some headwinds and get back to the historical figures. Our services to the Pharmaceutical industry have seen a promising uptick, demonstrating growth in both pre-clinical and analytical services. We have recently expanded our offerings to include clinical trials, which we anticipate will be a major driver of future growth. The Food segment experienced initial setbacks due to supply chain disruptions caused by various external factors. However, this segment has begun to recover and shows promise for continued improvement. Our new Electronics and Electrical testing division delivered strong results, while our other segments have gone through some corrections in services and their scale. Looking forward, we are confident in our ability to achieve significant growth. While FY24 presented unforeseen challenges, we are optimistic that FY25 will be a year of robust expansion for the company.” Result PDF
Conference Call with Vimta Labs Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Vimta Labs announced Q2FY24 & H1FY24 results: Total Income for Q2FY24 was at Rs 754 million a de-growth of 6.4% YoY EBITDA for Q2FY24 was Rs 179 million a decline of 31.4% YoY; EBITDA margin was at 23.8% Total Income for H1FY24 was at Rs 1,595 million a de-growth of 0.7% YoY EBITDA for H1FY24 was Rs 432 million a decline of 15.3% YoY; EBITDA margins at 27.1% Cash and Cash equivalents at Rs 262 million as of September 30, 2023 Cash flow From Operations at Rs 268 million for H1FY24; H1FY24 Capex at Rs 421 million Debt to Equity ratio 0.07 Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs, said, “The downtrend in our income has primarily stemmed from the Pharma and Food business, which saw decreased demand and lower volumes respectively. Conversely, our E&E; business continues to perform well, with Environment and Diagnostics remained stable. Given the headwinds from the broader economic uncertainties, we acknowledge the external challenges. However, our ongoing dialogues with clients along with the stability provided by our long-term contracts and revenue visibility for the H2FY24 keeps me optimistic of delivering growth in FY24.” Result PDF
Healthcare Services company Vimta Labs announced Q1FY24 results: Total Income for Q1FY24 was at Rs 841 million EBITDA for Q1FY24 was Rs 252 million; EBITDA margin remained steady at 30.0% Q1FY24 PAT was at Rs 122 million; PAT Margins for the quarter was at 14.5% Basic EPS was at Rs 5.5 in Q1FY24 as against Rs 5.4 in Q1FY23 Total Debt as of 30th June 2023 stood at Rs 137 million down from Rs 150 million as of 31st March 2023 Cash and Cash equivalents were at Rs 285 million as of 30th June 2023 Q1FY24 Capex was at Rs 218 million Debt to Equity ratio was 0.05x Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs, said: “We are extremely pleased with the continued growth momentum despite a challenging external environment. During Q1FY24, our total income was Rs 841 million. The Pharma segment led the growth during the quarter with the food segment getting impacted due to the Biparjoy cyclone whereas other segments remained stable. While the external environment remains uncertain, robust demand in the TIC market gives us the confidence of delivering strong growth in the coming quarters” Result PDF